RT Journal Article
T1 Crambescin C1 Exerts a Cytoprotective Effect on HepG2 Cells through Metallothionein Induction
A1 Roel Sánchez, María
A1 Rubiolo Gaytán, Juan Andrés
A1 Ternon, Eva
A1 Thomas, Olivier P.
A1 Rodríguez Vieytes, Mercedes
A1 Botana López, Luis Miguel
K1 Crambescin-C1
K1 Crambescin-A1
K1 Metallothionein
K1 Crambe crambe
K1 Sponge-derived compounds
K1 Transcriptome profiling
K1 Antioxidant effect
K1 Cell cycle inhibition
AB The Mediterranean marine sponge Crambe crambe is the source of two families of guanidine alkaloids known as crambescins and crambescidins. Some of the biological effects of crambescidins have been previously reported while crambescins have undergone little study. Taking this into account, we performed comparative transcriptome analysis to examine the effect of crambescin-C1 (CC1) on human tumor hepatocarcinoma cells HepG2 followed by validation experiments to confirm its predicted biological activities. We report herein that, while crambescin-A1 has a minor effect on these cells, CC1 protects them against oxidative injury by means of metallothionein induction even at low concentrations. Additionally, at high doses, CC1 arrests the HepG2 cell cycle in G0/G1 and thus inhibits tumor cell proliferation. The findings presented here provide the first detailed approach regarding the different effects of crambescins on tumor cells and provide a basis for future studies on other possible cellular mechanisms related to these bioactivities
PB MDPI
YR 2015
FD 2015
LK http://hdl.handle.net/10347/23611
UL http://hdl.handle.net/10347/23611
LA eng
NO Roel, M.; Rubiolo, J.A.; Ternon, E.; Thomas, O.P.; Vieytes, M.R.; Botana, L.M. Crambescin C1 Exerts a Cytoprotective Effect on HepG2 Cells through Metallothionein Induction. Mar. Drugs 2015, 13, 4633-4653
NO FEDER cofunded-grants. CDTI and Technological Funds, supported by Ministerio de Economía y Competitividad, AGL2012-40185-CO2-01 and Consellería de Cultura, Educación e Ordenación Universitaria, GRC2013-016, and by Axencia Galega de Innovación, Spain, ITC-20133020 SINTOX, IN852A 2013/16-3 MYTIGAL. CDTIunderISIP Programme, Spain, IDI-20130304 APTAFOOD. European Union’s 7th Framework Programme managed by Research Executive Agency (FP7/2007-2013) under grant agreement Nos. 265409 µAQUA, 315285 CIGUATOOLS and 312184 PHARMASEA
DS Minerva
RD 1 may 2026